Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ATRN-119 by Aprea Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Risk adjusted net present value: What is the current valuation of Aprea Therapeutics's ATRN-119?
ATRN-119 is a small molecule commercialized by Aprea Therapeutics, with a leading Phase II program in Ovarian Cancer;Cervical Cancer;Endometrial Cancer;Fallopian...
Risk adjusted net present value: What is the current valuation of Aprea Therapeutics's ATRN-119?
ATRN-119 is a small molecule commercialized by Aprea Therapeutics, with a leading Phase II program in Endometrial Cancer. According to...
ATRN-119 by Aprea Therapeutics for Ovarian Cancer: Likelihood of Approval
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...